IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 69, Issue 9, 2010, Pages 1704-1710

  Bassi, N ^a   Ghirardello, A ^a   Blank, M ^b   Zampieri, S ^a   Sarzi Puttini, P ^c   Mantovani, A ^d   Shoenfeld, Y ^b   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PENTRAXIN 3; PENTRAXIN 3 ANTIBODY; PHOSPHOLIPID ANTIBODY; PREDNISONE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RHEUMATIC DISEASES; SERUM AMYLOID P-COMPONENT; YOUNG ADULT;

EID: 77956025067     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117804     Document Type: Article

References (48)

1. Sherer Y, Gorstein A, Fritzler MJ, et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501-37. (Pubitemid 40288129)
2. Nauta AJ, Daha MR, van Kooten C, et al. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003;24:148-54.
3. Dieker JW, van der Vlag J, Berden JH. Deranged removal of apoptotic cells: its role in the genesis of lupus. Nephrol Dial Transplant 2004;19:282-5.
4. Gaipl US, Voll RE, Sheriff A, et al. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 2005;4:189-94. (Pubitemid 40704701)
5. Munoz LE, van Bavel C, Franz S, et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008;17:371-5.
6. Janko C, Schorn C, Grossmayer GE, et al. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 2008;8:9-12.
7. Castro J, Balada E, Ordi-Ros J, et al. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 2008;7:345-51.
8. Kavai M, Szegedi G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev 2007;6:497-502. (Pubitemid 47069975)
9. Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008;28:1-13.
10. Sjöwall C, Wetterö J. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clin Chim Acta 2007;378:13-23.
11. Manfredi AA, Rovere-Querini P, Bottazzi B, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008;20:538-44.
12. Gershov D, Kim S, Brot N, et al. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-64.
13. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008;59:1814-20.
14. Sen JW, Recke C, Rahbek L, et al. Structural, quantitative and functional comparison of amyloid P component in sera from patients with systemic lupus erythematosus and healthy donors. Scand J Immunol 2002;56:645-51.
15. Bijl M, Horst G, Bijzet J, et al. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum 2003;48:248-54. (Pubitemid 36091670)
16. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300-6.
17. Baruah P, Dumitriu IE, Peri G, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 2006;80:87-95.
18. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005;25:582-91.
19. Kravitz MS, Shoenfeld Y. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2006;2:481-90. (Pubitemid 44340424)
20. Gaipl US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006;9:173-87.
21. Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules - C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:227-39.
22. Sjöwall C, Bengtsson AA, Sturfelt G, et al. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004;6:R87-94.
23. Zandman-Goddard G, Blank M, Langevitz P, et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 2005;64:1698-702.
24. Figueredo MA, Rodriguez A, Ruiz-Yagüe M, et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006;33:1980-6. (Pubitemid 44571870)
25. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, et al. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2009;39:38-54.
26. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817-23.
27. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007;204:793-804.
28. Jaillon S, Jeannin P, Hamon Y, et al. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ 2009;16:465-74.
29. Augusto JF, Onno C, Blanchard S, et al. Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:442-4.
30. American College of Rheumatology Ad Hoc on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
31. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-64.
32. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
33. Bernatsky S, Clarke A, Abrahamowicz M, et al. A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. J Rheumatol 2005;32:820-3. (Pubitemid 40676489)
34. Burland TG. DNASTAR's Lasergene sequence analysis software. Methods Mol Biol 2000;132:71-91.
35. Luchetti MM, Piccinini G, Mantovani A, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:196-202. (Pubitemid 30064610)
36. Bevelacqua V, Libra M, Mazzarino MC, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
37. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-50.
38. Rovere P, Sabbadini MG, Fazzini F, et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000;43:1663-72.
39. van Rossum AP, Pas HH, Fazzini F, et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006;54:986-91.
40. Salustri A, Garlanda C, Hirsch E, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004;131:1577-86.
41. Lesley J, Gál I, Mahoney DJ, et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem 2004;279:25745-54. (Pubitemid 38756838)
42. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003;33:465-73.
43. Nauta AJ, de Haij S, Bottazzi B, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 2005;67:543-53.
44. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol 1993;150:1804-12. (Pubitemid 23129656)
45. Bussolati B, Peri G, Salvidio G, et al. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 2003;170:1466-72. (Pubitemid 36139516)
46. Zhu L, Yang X, Ji Y, et al. Up-regulated renal expression of TNF-alpha signalling adapter proteins in lupus glomerulonephritis. Lupus 2009;18:116-27.
47. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006;65:545-8.
48. Kallenberg CG. Anti-C1q autoantibodies. Autoimmun Rev 2008;7:612-15.